LOUISIANA WHOLESALE DRUG CO., INC. v. SMITHKLINE BEECHAM CORPORATION et al

  1. February 28, 2023

    Buyers Don't Qualify As Class In Lamictal Antitrust Case

    Buyers of a generic epilepsy drug aren't so numerous that they must be allowed to band together in a class action rather than joining their suits together traditionally, said a New Jersey federal judge who has refused to certify their class in an antitrust suit against drugmakers GlaxoSmithKline and Teva Pharmaceuticals.

  2. February 02, 2023

    Lamictal Drug Buyers Lose Another Class Certification Bid

    A proposed class of drug wholesalers accusing GlaxoSmithKline PLC and Teva Pharmaceuticals Ltd. of suppressing the generic competition to the epilepsy treatment and mood stabilizer Lamictal has failed to convince a New Jersey federal judge to certify it on its second attempt.

  3. December 21, 2021

    DOJ Opioid Trial Team Tainted By Kirkland Ties, Ex-CEO Says

    A U.S. Department of Justice lawyer who acquired "inside knowledge" about a drug distributor while at Kirkland & Ellis has seemingly been enlisted to exploit that knowledge in the opioid prosecution of the distributor's ex-CEO, and the DOJ's entire trial team should be disqualified, according to filings in New York federal court.

  4. April 09, 2021

    NJ Judge Denies Class Cert. For Generic Lamictal Buyers

    A New Jersey federal judge on Friday declined to certify a proposed class of drug wholesalers who accused GlaxoSmithKline PLC and Teva Pharmaceuticals Ltd. of stifling generic competition for the mood stabilizer Lamictal, reversing a previous judge's decision.

  5. March 09, 2020

    3rd Circ. Signals Disapproval Of Lamictal Antitrust Class Cert.

    The Third Circuit questioned a district court's certification of a class of drug wholesalers who lodged pay-for-delay claims against GlaxoSmithKline PLC and Teva Pharmaceuticals Ltd. over the generic version of the mood stabilizer Lamictal, noting Monday that the wholesalers engaged in individualized negotiations to purchase the drugs.

  6. March 22, 2019

    Lamictal Antitrust Class Action Paused For Certification Fight

    A New Jersey federal judge agreed Friday to pause a class action alleging a pay-for-delay scheme over the mood stabilizer Lamictal while GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. fight the case's class certification in the Third Circuit, despite drug wholesalers' objections to delaying proceedings in the long-running case.

  7. March 18, 2019

    3rd Circ. To Hear Class Cert. Appeal In Lamictal Case

    The Third Circuit on Monday agreed to hear an appeal from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. as they look to nix a class certification for buyers accusing the drugmakers of delaying generic alternatives to the mood stabilizer Lamictal.

  8. February 15, 2019

    Lamictal Case Won't Be Paused For Class Cert. Appeal

    A New Jersey federal judge on Friday refused to pause a case accusing GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. of delaying the entry of generic alternatives to epilepsy drug Lamictal while the drugmakers try to appeal a class certification ruling to the Third Circuit.

  9. January 22, 2019

    Direct Buyers Fight GSK, Teva's Bid To Stay Lamictal Suit

    Drug wholesalers urged a New Jersey federal court Monday to nix a bid from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. to pause an antitrust suit over the availability of generic alternatives to epilepsy drug Lamictal while the companies seek Third Circuit review of the direct buyers' class certification.

  10. January 04, 2019

    Teva, GSK Want Lamictal Suit Paused To Appeal Class Cert.

    GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. are aiming to dismantle drug wholesalers' newly secured class certification in an antitrust battle centered on the availability of generic options to brand-name epilepsy drug Lamictal, asking a New Jersey federal court Thursday to put the case on hold while they appeal the class's win.